Cidara Therapeutics Inc
Change company Symbol lookup
Select an option...
CDTX Cidara Therapeutics Inc
XBTAX BlackRock Long Term Municipal Advantage Trust
PBYA Probility Media Corp
RA Brookfield Real Assets Income Fund Inc.
PAA Plains All American Pipeline LP
$ESDOWD DOW JONES SPAIN STK US$ NDX
GOOGL Alphabet Inc
WFC Wells Fargo & Co
BAC Bank of America Corp
BA Boeing Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Closing Price
$3.67
Day's Change
0.01 (0.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.81
Day's Low
3.64
Volume
(Light)
Volume:
174,772

10-day average volume:
624,062
174,772

Jack in the Box pulls 2020 guidance due to coronavirus

4:27 pm ET April 15, 2020 (MarketWatch)
Print

Jack in the Box Inc. (JACK) said late Wednesday that it was withdrawing its 2020 guidance due to the COVID-19 pandemic and was projecting a quarterly same-store sales decrease of 4.2%. Jack in the Box shares rose 0.4% in the extended session. The company said that it had minimal temporary closures and were operating in an "off-premise" capacity. Jack in the Box said it had paused its share repurchase program and did not buy back shares in the second quarter, which ended April 12. The restaurant chain said it expects to report $165 million in cash at the end of the second quarter and that it will update when it can estimate the impacts of the coronavirus on its operations.

-Max A. Cherney; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

April 15, 2020 16:27 ET (20:27 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.